GlassScriptPhysician profile
William Clifford Mitchell
NPI 1568433571
$15,849.05
in general payments reported to CMS, 2019-2025
54 companies · $2,390 in 2025
The $2,390 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,226 · 2020: $1,328 · 2021: $1,250 · 2022: $2,424 · 2023: $2,368 · 2024: $2,863 · 2025: $2,390.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,601 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,601.18 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,290.39 | 2019-2025 | |
| Novo Nordisk INC | $2,019.01 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,795.07 | 2019-2025 | Airsupra, Farxiga, Bevespi Aerosphere |
| Pfizer INC. | $1,165.43 | 2019-2025 | |
| Lilly USA, LLC | $946.49 | 2019-2025 | Mounjaro, Trulicity, Jardiance |
| Glaxosmithkline, LLC. | $594.81 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $560.11 | 2019-2025 | Jardiance, Tradjenta, Synjardy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $513.25 | 2019-2025 | Xifaxan |
| Amgen INC. | $507.13 | 2019-2024 | Otezla, Repatha |
| Astellas Pharma US INC | $487.51 | 2019-2025 | Veozah, Myrbetriq |
| Novartis Pharmaceuticals Corporation | $478.02 | 2019-2024 | |
| Allergan, INC. | $436.16 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $344.20 | 2019-2023 | Verquvo, Belsomra, Steglatro |
| Exact Sciences Corporation | $318.15 | 2023-2025 | Cologuard Collection Kit |
| Shield Therapeutics INC | $300.37 | 2023-2025 | Accrufer |
Show all 54 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Mitchell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.